US equities |
SPCX $167.40 ▲+5.31% NVDA $236.47 ▲+1.08% MU $1,068.45 ▼-0.60% TSLA $379.02 ▲+2.28% MSFT $526.25 ▲+1.68% SNDK $1,713.40 ▼-0.38% INTC $117.12 ▼-1.85% META $744.66 ▲+2.28%
FinancialContent

Alpha Cognition Inc. - Common Stock (NQ:ACOG)

9.025 -0.075 (-0.82%)
Delayed Quote Updated: 12:46 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alpha Cognition Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Alpha Cognition Inc.
Via Business Wire
News headline image
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26
Dallas, Texas--(Newsfile Corp. - August 17, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on... 
Via Newsfile
News headline image
Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease
From Alpha Cognition, Inc.
Via Business Wire
News headline image
Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences
From Alpha Cognition, Inc.
Via Business Wire
News headline image
Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury
From Alpha Cognition Inc.
Via Business Wire
News headline image
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425
Dallas, Texas--(Newsfile Corp. - April 1, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on... 
Via Newsfile
News headline image
Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer’s Association International Conferences
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution
From Alpha Cognition, Inc.
Via Business Wire
News headline image
Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners
From Alpha Cognition Inc.
Via Business Wire
News headline image
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025
Dallas, Texas--(Newsfile Corp. - November 14, 2025) - Alpha... 
Via Newsfile
News headline image
Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition, Inc. to Present at Spartan Capital Securities' Second Annual Investor Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
< Previous 1 2 3 Next >